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Abstract
The organic anion transporting polypeptide 4c1 (Oatp4c1) was previously identified as a novel uptake transporter
predominantly expressed at the basolateral membrane in the rat kidney proximal tubules. Its functional role was suggested
to be a vectorial transport partner of an apically-expressed efflux transporter for the efficient translocation of physiological
substrates into urine, some of which were suggested to be uremic toxins. However, our in vitro studies with MDCKII cells
showed that upon transfection rat Oatp4c1 polarizes to the apical membrane. In this report, we validated the trafficking and
function of Oatp4c1 in polarized cell systems as well as its subcellular localization in rat kidney. Using several
complementary biochemical, molecular and proteomic methods as well as antibodies amenable to immunohistochemistry,
immunofluorescence, and immunobloting we investigated the expression pattern of Oatp4c1 in polarized cell systems and
in the rat kidney. Collectively, these data demonstrate that rat Oatp4c1 traffics to the apical cell surface of polarized
epithelium and localizes primarily in the proximal straight tubules, the S3 fraction of the nephron. Drug uptake studies in
Oatp4c1-overexpressing cells demonstrated that Oatp4c1-mediated estrone-3-sulfate (E3S) uptake was pH-dependent and
ATP-independent. These data definitively demonstrate the subcellular localization and histological location of Oatp4c1 and
provide additional functional evidence that reconciles expression-function reports found in the literature.
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Introduction
The kidney is responsible for homeostasis of endogenous and
exogenous substances through tubular secretion and reabsorption,
which in part is mediated by various membrane transporters,
including the solute carrier family (SLC) and ATP-binding cassette
(ABC) superfamily. Several studies have demonstrated that
overlapping substrate specificity among uptake and efflux trans-
porters is likely to accelerate the translocation of endogenous and
exogenous substances across epithelial or endothelial barriers
[1,2]. Three members of the rodent Oatp family have been
identified in the rat kidney proximal tubules. Oatp1a1 (previously:
Oatp1) and Oatp1a3 (previously: Oat-k1, Oat-k2) are expressed at
apical membranes [3,4], and Oatp4c1 (previously: Oatp-H) was
reported to be expressed at the basolateral membrane of the
proximal tubule [5]. OATP4C1 is the only OATP detected in
renal proximal tubules [6]. The reported substrates of OATP4C1
include cardiac glycosides (digoxin and ouabain), thyroid hor-
mones (triiodothyronine (T3) and thyroxine (T4)), cAMP, metho-
trexate (MTX) [5], sitagliptin [7], and estrone-3-sulfate (E3S) [8].
The transporter has been shown to have unidirectional uptake
function, but the driving force has not yet been elucidated.
Mikkaichi et al. showed that sodium, chloride ion, and pH do not
affect OATP4C1-mediated uptake, while ATP depletion partially
inhibits T3 uptake to 40% [5]. In contrast, Leuthold et al.
demonstrated that OATP4C1-mediated E3S or T4 uptake is
significantly higher at extracellular pH 6.5 than pH 8.0 [9]. In
addition, OATP4C1 has been suggested to possess multiple
substrate recognition sites, because digoxin does not inhibit
OATP4C1-mediated T3 [5] or E3S [8] uptake and vice versa,
while E3S and T3 have mutual inhibition. Furthermore, the
physiological role of OATP4C1, reportedly a basolateral uptake
transporter, has been postulated to be coupling with P-glycopro-
tein, an apical efflux transporter, to facilitate the renal clearance of
common substrates such as digoxin [5] and uremic toxins [10]. In
studies with transgenic rats harboring human SLCO4C1, the
decrease of uremic toxin (guanidino succinate, asymmetric
dimethylarginine, and trans-aconitate) concentrations in plasma
suggests that OATP4C1 may facilitate the excretion of uremic
toxins in renal failure models and, by extension, in patients with
chronic kidney disease. However, direct evidence that these toxins
are OATP4C1 substrates is lacking.
In addition to the kidney, there are limited data regarding the
expression of OATP4C1. Microarray expression has shown that
human SLCO4C1 is also expressed in the liver, lung, mammary
gland, skin, neutrophils, peripheral leukocytes and mononuclear
cells [6]. Rat Slco4c1 is detected mainly in the kidney and lung,
and slightly in the brain by Northern Blot analysis [5]. To further
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study the role of this transporter in drug disposition, we sought to
generate transfected cell lines expressing rat Oatp4c1. Initial
attempts in our laboratory to generate Oatp4c1-expressing
MDCKII cells produced unexpected results as the transporter
localized at the apical rather than the basolateral membranes.
Although this result was unexpected, it is not without precedent.
Previous work by Lai and Tan showed that MRP4 was localized in
the basolateral membrane of MDCKII cells [11]. However,
MRP4 localizes at the apical membrane of human and rodent
renal tubules [12]. This discrepancy was later attributed to species
differences in Na+/H+ exchanger regulatory factor 1 (NHERF1)
expression, an adaptor protein, which determines the trafficking of
MRP4 [13]. In this study we sought to definitively demonstrate the
subcellular localization of Oatp4c1 in the in vitro models and in rat
tissues. We used a comprehensive approach including multiple
antibodies amenable to immunohistochemistry, immunofluores-
cence, and immunobloting to probe the expression of rat Oatp4c1
in intact tissues and cells as well as biochemically separated and
enriched apical and basolateral membranes isolated from polar-
ized cells and renal proximal tubules. Furthermore, proteomic
analysis was used to qualitatively validate the specificity of our
antibody. Functional activity of Oatp4c1 in MDCKII-Oatp4c1
was probed with E3S. Collectively, our data provide evidence that
is contrary to published work regarding the localization, polarity,
and function of Oatp4c1.
Methods
Ethics Statement
Tissues from animals were collected using procedures formally
approved by the University of Kentucky Institutional Animal Care
and Use Committee protocol# 2007-0228. All cell culture
procedures and cell-line modifications were performed with
approval from the Institutional Biosafety committee at the
University of Kentucky under application B07-598.
Chemicals
[3H]-E3S (45.6 Ci/mmol) was from Perkin Elmer (Waltham,
MA). GF120918 was a gift from GlaxoSmithKline (Research
Triangle Park, NC). All other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO) unless specified otherwise. All
procedures involving the culture and manipulations of cell lines
were approved by the University of Kentucky Biological Safety
Committee.
Antibodies
Rabbit polyclonal anti-Oatp4c1 antibodies were generated
(Open Biosystems, Rockford, IL) against sequence peptides of
rat Oatp4c1. Two amino-terminus [KGVENPAFVPSSPDTPRR
(PA1254); QPRESEDPQKSTEPS (F3608)], two carboxyl-termi-
nus [STITVEEDLNKIENEG (PA1343); TVEEDLNKIENEG
(PA1562)], and an extracellular loop [SPDFEARAGKC
(PA1556)] previously reported by Mikkaichi and colleagues [5].
PA1343 was affinity-purified. Rabbit polyclonal anti-Abcg2
antibodies were generated (Open Biosystems) against Walker A
peptide (GKSSLLDVLAARKD) of rat Abcg2 [14] and were used
to determine the expression of Abcg2 in brush border membranes
by western blot. Rat monoclonal antibody against E-cadherin
(DECMA-1), mouse monoclonal antibodies against calbindin-D28k
(CB-955) and aquaporin 1 (1/22) were obtained from Abcam
(Cambridge, MA). Mouse monoclonal antibody against ZO-1
(zo1-1A12) was from Invitrogen. Mouse monoclonal antibody
against b-actin (AC-15) was from Sigma-Aldrich. Mouse mono-
clonal antibody against P-gp (C219) was from Signet (Dedham,
MA). Rat monoclonal antibody against rat Abcg2 (BXP-53) and
Mrp4 (M4I-10) were from Kamiya (Seattle, WA). Rabbit
polyclonal antibody against Na+/K+-ATPase (#3010) was ob-
tained from Cell Signaling (Danvers, MA).
Construction of Plasmid Vector
Total RNA was isolated from a frozen kidney of a Sprague-
Dawley rat using RNeasy Kit (Qiagen, Valencia, CA) as directed
by the manufacture including on-column DNA digestion, and then
reverse-transcribed to cDNA using ThermoScriptTM RT-PCR kit
(Invitrogen) with oligo (dT)20 primers according to the manufac-
turer’s protocol. Rat Slco4c1 cDNA was amplified using Phusion
High-Fidelity PCR kit (New England Biolabs, Ipswich, MA) with
forward (59- CACCATGCAGGGTTCCAAGGGAG-39) and
reverse (59- CTATCCTTCGTTCTCTATTTTGTTG-39) prim-
ers. Amplification conditions were as follows: 98uC (1 min), [98uC
(10 sec), 64uC (30 sec), 72uC (35 sec)] 640 cycles, 72uC (10 min).
The amplified fragment was purified using ZymocleanTM Gel
DNA Recovery kit (Zymo Research, Irvine, CA). The subsequent
sequence was cloned into the vector pENTR (Invitrogen) and the
construct was transformed into competent One Shot TOP10 E.
coli cells (Invitrogen). The plasmid DNA was isolated from a
positive transformant using QIAprep Spin Miniprep Kit (Qiagen)
according to the manufacturer’s protocol. The sequence was
confirmed (Davis sequencing, Davis, CA) to share 100% identity
with rat Slco4c1 sequence (GeneBank accession number
NM_001002024). The plasmid DNA was then subcloned into
the multiple cloning site of the mammalian expression vector
pcDNA6.2/GFP-DEST (Invitrogen).
Cell Culture and Transfection
Madin-Darby canine kidney II (MDCKII) cells (European
Collection of Cell Cultures, Salisbury, UK) were cultured in
minimum essential medium with Earle’s salts (MEM, Mediatech,
Manassas, VA) supplemented with 5% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA), 100 U/ml penicillin, and
100 mg/ml streptomycin (Invitrogen) at 37uC in a humidified
incubator with 5% CO2. LLC-PK1 cells (kind gift from Dr. Alferd
Schinkel [15], Netherlands Cancer Institute) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin. The pcDNA6.2/GFP-DEST-rat
Slco4c1 and pcDNA6.2/GFP-DEST were transfected into
MDCKII and LLC-PK1 cells using FuGENE6 reagent (Roche
Diagnostics Co., Indianapolis, IN) according to the manufacturer’s
instructions. The transfected cells were selected with 5 mg/ml
blasticidin (Invitrogen). It should be noted that under these
experimental conditions pcDNA6.2/GFP-DEST expresses only
the gene of interest (Slco4c1) because we did not use Tag-On-
Demand Suppressor Supernatant (Invitrogen) to induce a GFP
fused Oatp4c1. Rat Oatp4c1 expression was assessed by western
blot analysis and immunohistochemical analysis. The subcellular
localization in pooled cells was examined by surface protein
biotinylation assay (described below), and confocal microscopy. A
clone with the highest Oatp4c1 expression was obtained by serial
dilution and was used for uptake studies.
Western Blot Analysis
Cell lysates were prepared from Oatp4c1-expressing and vector-
transfected MDCKII cells. Following a wash with ice-cold PBS,
cells were scraped and pelleted by centrifugation at 300 g for
5 min. Cell pellets were resuspended in RIPA buffer (50 mM Tris,
150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM
Oatp4c1 Expression in Rat Kidney
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EDTA, 0.1% SDS, pH 8.0) with protease inhibitor cocktail
(Roche Diagnostics Co.) and shaken at 4uC for 30 min.
Crude membrane fractions were prepared from Sprague-
Dawley female rat tissues. The tissues were disrupted in Dounce
Buffer (10 mM Tris, 0.5 mM MgCl2, protease inhibitor cocktail,
pH 7.6) with brief pulses of sonication using a probe ultrasonic
processor (Thermo Fisher Scientific) at 4uC and tonicity was
restored to 150 mM with NaCl. Following 300 g centrifugation for
5 min, EDTA was added to the supernatant to a final
concentration of 5 mM. The samples were centrifuged at
100,000 g for 1 hr at 4uC. Pellets were resuspended in buffer
(0.2 M mannitol, 0.07 M sucrose, 50 mM Tris HCl, 1 mM EDTA).
Protein concentrations were measured using a bicinchoninic acid
assay (BCA Protein Assay Kit, Thermo Fisher Scientific,
Waltham, MA). Cell lysates and crude membrane fractions were
stored at 280uC until use.
Cell lysates and crude membrane fractions were mixed with
NuPAGE LDS sample buffer (Invitrogen) and 0.1 M dithiothreitol
before incubation at 70uC for 10 min. Proteins were separated on
a 10% SDS-polyacrylamide gel with 5% stacking gel and
transferred to a polyvinylidene difluoride membrane (Millipore,
Billerica, MA) at 200 mA for 2 hr at 4uC. Following blocking with
5% skimmed milk in phosphate buffered saline with 0.05%
Tween-20 (PBST) for 3 hr at room temperature, the membranes
were incubated with 55 mg/ml anti-Oatp4c1 polycolonal antibody
(PA1343) in 5% skimmed milk in PBST overnight at 4uC. After
washing with PBST, membranes were incubated with HRP
conjugated goat anti-rabbit IgG (Thermo Fisher Scientific) in 5%
skimmed milk in PBST for 1 hr at room temperature. Following
washing with PBST, a standard ECL kit (Thermo Fisher Scientific,
Rockford, IL) and Image Station 2000 MM (Eastman Kodak,
Rochester, NY) were used for visualization.
Immunofluorescence Microscopy
Oatp4c1-expressing and vector-transfected MDCKII cells were
grown on Snapwell polycarbonate filter membranes (0.4 mm pore
size, 1.12 cm2 growth area, Corning Costar, Lowell, MA) for 4
days to achieve transepithelial electrical resistance .200 VNcm2.
Filter membranes were washed with ice-cold PBS, excised and
processed for staining. After fixation with 220uC methanol for
10 min, rehydration with PBS for 5 min, permeabilization (0.2%
triton X-100 in PBS) for 15 min, and blocking with 10% goat
serum for 1 hr, cells were incubated with the rabbit anti-Oatp4c1
polyclonal antibody (PA1343, 110 mg/ml) and mouse anti-ZO-1
monoclonal antibody (5 mg/ml) for 2 hr at room temperature.
Following washes with permeabilization solution, cells were
incubated with 4 mg/ml Alexa Fluor 568 goat anti-rabbit IgG
and Alexa Fluor 488 anti-mouse IgG (Invitrogen) for 1 hr at room
temperature. Cells were washed with permeabilization solution
and mounted on glass slides with Prolong GoldH containing DAPI
solution (Invitrogen) to visualize nuclei. The fluorescence emission
was visualized using Axiovert 200 M confocal microscope (Carl
Zeiss, Thornwood, NY).
Surface Protein Biotinylation Assay
Oatp4c1-expressing and vector-transfected MDCKII cells were
grown on Transwell polycarbonate filter membranes (3 mm pore
size, 4.67 cm2 growth area, Corning Costar) for 4 days to achieve
transepithelial electrical resistance .200 VNcm2. Cells were
washed with ice-cold PBS-Mg/Ca buffer (PBS buffer containing
0.1 mM CaCl2 and 1 mM MgCl2). Freshly prepared Sulfo-NHS-
SS-Biotin (1 mg/ml in PBS with Mg++/Ca++) was added to either
the apical or basolateral chamber and incubated with slow rocking
at 4uC for 20 min. Cells were then washed and incubated with
quenching buffer (5 mM glycine in PBS-Mg/Ca) with slow
rocking at 4uC for 20 min to remove unreacted biotin. Following
washing with PBS with Mg++/Ca++, cells were lysed with 700 ml
lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1%
SDS, 1% Triton X-100, pH 7.4, with protease inhibitor cocktail)
for 30 min at 4uC with shaking. Cell lysates were centrifuged at
10,000 g for 2 min at 4uC and supernatants were incubated with
streptavidin agarose beads with end-over-end rotation for 1 hr at
4uC. Samples were washed three times with lysis buffer and
incubated with 50 ml 2X Laemmli Buffer (125 mM Tris, 10%
glycerol, 2%SDS, 5% 2-b-mercaptoethanol, pH 6.8) for 30 min at
room temperature. 2-b-mercaptoethanol was used to break the
sulfhydryl (SS) bond between the biotin and the protein reactive
group releasing the biotinylated membrane proteins from the
beads. Samples were centrifuged at 10,000 g for 2 min, and the
supernatants were subjected to western blot analysis.
Immunohistochemistry
Female Sprague-Dawley rat liver and kidney were isolated and
fixed in 4% paraformaldehyde for 6 hr at room temperature. The
tissues were embedded in paraffin using standard histology
techniques, and cut as 6 mm-thick sections. After deparaffinization
and rehydration in xylene and ethanol gradient solutions, the antigen
was retrieved under pressure in 10 mM citrate buffer, pH 6.0.
Sections were blocked with 3% H2O2 in PBS for 10 min and treated
with avidin and biotin blocking reagent (Vector Laboratories,
Burlingame, CA) for 15 min each. Non-specific interactions were
blocked with 2% normal goat serum in PBST for 30 min prior to
incubating with 220 mg/ml anti-Oatp4c1 antibody (PA1343) for
24 hr at room temperature. For visualization, sections were
incubated with 5 mg/ml biotinylated goat anti-rabbit IgG (Vector
Laboratories) for 30 min at room temperature, Streptavidin-HRP
reagent (Dako, Carpinteria, CA) for 20 min and NovaRED
chromogen substrate (Vector Laboratories) for 5 min. After coun-
terstaining with hematoxylin and dehydration, the sections were
mounted with Vecta-Mount (Vector Laboratories).
To further study the localization of Oatp4c1, the rat tissue
sections were double stained with anti-Oatp4c1 antibody (PA1343,
110 mg/ml) and the following antibodies: anti-E-cadherin (2 mg/
ml), anti-AQP1 (10 mg/ml), and anti-calbindin-D28k (40 mg/ml),
anti-Abcg2 (BXP-53, 12.5 mg/ml), anti-Mrp4 (3 mg/ml), anti-P-gp
(2.5 mg/ml). For visualization, the sections were then incubated
with fluorescence conjugated secondary antibodies for 30 min at
room temperature and then mounted with Prolong GoldH DAPI
containing solution. The fluorescence emission was visualized
using Axiovert 200 M confocal microscope (Carl Zeiss, Thorn-
wood, NY).
BBM (Brush-border Membrane) and BLM (Basolateral
Membrane) Isolation
The BBM and BLM were isolated by Percoll density gradient
centrifugation according to procedures described by Goldinger et
al. with some modifications [16]. Briefly, two male Sprague-
Dawley rats were euthanized by rapid decapitation and the
kidneys were excised and frozen immediately in liquid nitrogen.
Frozen kidney cortex tissues were excised and homogenized in
sucrose buffer (250 mM sucrose, 10 mM triethanolamine, pH 7.4,
protease inhibitor cocktail) with a motorized homogenizer.
Samples were centrifuged at 2,500 g for 15 min at 4uC. The
supernatant was centrifuged at 20,000 g for 20 min at 4uC. The
less dense top layer of the pellet was collected and the lower dark
segment of the pellet was discarded. The pellet was resuspended in
26.5 ml sucrose buffer with 10 strokes of a tight plunger in a
Dounce homogenizer. Following addition of 3.5 ml Percoll the
Oatp4c1 Expression in Rat Kidney
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suspension was mixed by inversion and centrifuged at 48,000 g for
30 min at 4uC. Two distinct bands were formed and carefully
isolated. The upper band was BLM and the lower one was BBM
[16]. An equal volume of sucrose buffer was added to each
fraction, and the Percoll was removed by centrifuging at 93000 g
for 1 hr at 4uC. The single band of membrane proteins was
collected and the glassy Percoll pellet was discarded. The BLM
was resuspended in mannitol buffer (150 mM mannitol, 2.5 mM
EGTA, 6 mM HEPES, pH 7.4). The BBM pellet was further
purified by magnesium precipitation [17]. Following resuspension
in buffer (100 mM mannitol, 1.6 mM EGTA, 0.3 mM PMSF,
0.3 mM sodium orthovanadate, 4 mM HEPES, pH 7.4), MgCl2
was added to yield a final concentration of 12 mM. The mixture
was incubated on ice for 15 min with intermittent and gentle
mixing. Remaining cellular debris were removed by centrifuging
at 3,000 g for 10 min at 4uC, the resultant supernatant was
centrifuged at 30,000 g for 40 min at 4uC to isolate membrane
proteins. The BBM pellet was resuspended in mannitol buffer and
again precipitated by addition of 12 mM MgCl2 as described
above. The final pellet was resuspended in mannitol buffer. The
BBM and BLM were stored at 280uC until use. Separation
efficiency was evaluated by western blot analysis with anti- Na+/
K+-ATPase (1:1000), anti-Mrp4 (3 mg/ml) and anti-Abcg2
(150 mg/m).
Protein Trypsin Digestion and LC-MS/MS Analysis
Approximately 100 mg of proteins from the BBM and BLM
were subjected to 10% SDS-PAGE separation. The protein gel
bands at ,65–100 and ,100–150 kDa were excised and
underwent dithiothreitol reduction, iodoacetamide alkylation,
and in-gel trypsin digestion using a standard protocol as previously
reported [18,19]. The resulting tryptic peptides were extracted,
concentrated to 15 ml each using a SpeedVac, and 5 ml was
injected for nano-LC-MS/MS analysis. LC-MS/MS data were
acquired on an LTQ Velos Orbitrap mass spectrometer (Thermo
Fisher Scientific, Waltham, MA) coupled with a Nano-LC Ultra/
cHiPLC-nanoflex HPLC system (Eksigent, Dublin, CA) through a
nano-electrospray ionization source. The tryptic peptides sample
was injected by an autosampler, desalted on a trap column, and
subsequently separated by reverse phase C18 column (75 mm
i.d.6150 mm) at a flow rate of 250 nL/min. The HPLC gradient
was linear from 5% to 60% mobile phase B for 30 min using
mobile phase A (H2O, 0.1% formic acid) and mobile B (90%
acetonitrile, 0.1% formic acid). Eluted peptides were analyzed
using data-dependent acquisition: peptide mass spectrometry was
obtained by Orbitrap with a resolution of 60,000. The seven most
abundant peptides were subjected to collision induced dissociation
and MS/MS analysis in LTQ linear trap. The LC-MS/MS data
were submitted to a local MASCOT server for MS/MS protein
identification search via the ProteomeDiscoverer software. The
mass error tolerance was 5 ppm for peptide MS and 0.8 Da for
MS/MS. All peptides were required to have an ion score greater
than 30 (P,0.05). The false discovery rate in each LC-MS/MS
analysis was set to be less than 1%.
[3H]-E3S Uptake and Inhibition Studies
Oatp4c1-expressing and vector-transfected MDCKII cells
were grown in 6-well plates. The cell culture medium was
replaced with that containing 5 mM sodium butyrate to induce
transporter expression 24 hr prior the uptake study [20]. The
uptake buffer used in all transport experiments contained
118 mM NaCl, 23.8 mM NaHCO3, 4.83 mM KCl,
0.96 mM KH2PO4, 1.20 mM MgSO4, 5.0 mM glucose and
1.53 mM CaCl2. Buffer pH was adjusted to 7.4 by supplemen-
tation with 12.5 mM HEPES and pH adjustment with 1 M
Tris-base. Alternatively, the buffer was supplemented with
12.5 mM 2-(N-morpholino)ethanesulfonic acid and pH was
adjusted to 4.5 or 5.5 with 1 M Tris-base. Before the study,
cells were washed once and preincubated with uptake buffer for
15 min at 37uC. Uptake was initiated by replacing the uptake
buffer with that containing [3H]-E3S. After incubation for
designated time at 37uC, cells were washed three times with ice-
cold PBS, lysed with 0.5 ml of 0.5 N NaOH and neutralized
with 0.1 ml of 2.5 N HCl. The intracellular radioactivity was
determined by transferring 0.5 ml of lysate into scintillation
cocktail (Research product international, Mt. Prospect, IL) for
counting with a Packard 2200 CA Tri-Carb (PerkinElmer,
Waltham, MA) liquid scintillation counter. Protein concentra-
tions were measured using the BCA Protein Assay kit. Net
uptake was calculated as the difference between [3H]-E3S
uptake into Oatp4c1-expressing cells and uptake into the vector-
transfected cells. For [3H]-E3S uptake under ATP-depletion
conditions, cells were pre-incubated for 20 min prior to the
experiment and during the experiment (1 min) with uptake
buffer containing 20 mM 2-deoxy-D-glucose and 10 mM NaN3
without D-glucose [21]. For [3H]-E3S uptake inhibition, cells
were pre-incubated for 15 min prior to and during the
experiment (1 min) with 100 mM of various compounds at
pH 5.5 or 7.4. Based on model fitting criteria, transport
parameters were estimated using a sigmoid-Emax equation:
v~Tmax|S
n=(Sn
50
zSn)
Where, n, S, Tmax, S50, and n represent the initial uptake
velocity, substrate concentration, maximum uptake transport
velocity, Michaelis-Menten constant equivalent, and Hill coef-
ficient, respectively. The model was fitted to the data (obtained
in triplicate) by nonlinear regression using GraphPad Prism
(GraphPad Software, San Diego, CA).
Statistical Analysis
Values are presented as means 6 S.D. Statistical analysis was
performed with unpaired student’s t-test or two-way ANOVA and
Bonferroni post-hoc test for multiple comparisons. p,0.05 was the
criterion of statistical significance. GraphPad Prism was used for
all statistical analysis (GraphPad Software, San Diego, CA).
Results
Expression and Polarity of Rat Oatp4c1 in Polarized Cell
Lines
To study the role of rat Oatp4c1 in drug disposition, we
generated rat Oatp4c1-expressing MDCKII cells. The expression
of Oatp4c1 in the transfected cells were verified by western
blotting using the antibody (PA1343) generated against C-terminal
of rat Oatp4c1 (Fig. 1A). Oatp4c1 expression was detectable as a
band at ,80 kDa in MDCKII-Oatp4c1 cells, but not in
MDCKII-pcDNA (empty vector) cells. Expression was also
confirmed in paraformaldehyde-fixed paraffin-embedded cell
pellet sections by immunohistochemical analysis (Fig. 1B).
Oatp4c1 was observed on the cell membrane (Fig. 1B, inset) in
the MDCKII-Oatp4c1 cells, and no staining was observed in the
negative control (rabbit IgG) or in the MDCKII-pcDNA cells.
This demonstrated that the transfection was successful and that the
antibody was specific.
Subsequently, we sought to determine the subcellular
localization of Oatp4c1 in polarized cell monolayers by confocal
Oatp4c1 Expression in Rat Kidney
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immunofluorescence laser scanning microscopy (Fig. 1C). A
tight-junction protein, ZO-1, was used as an apical marker. As
shown in Fig. 1C, Oatp4c1 localizes at the apical membrane,
along with ZO-1, in MDCKII-Oatp4c1 cells. This result was
unexpected because Oatp4c1 was shown at the basolateral
membrane in the rat proximal tubule [5]. This result was also
confirmed by an alternate method. We used surface protein
biotinylation to determine Oatp4c1 expression in membrane
fractions obtained from polarized cell monolayers. The surface
proteins on either apical or basolateral membranes were labeled
with biotin and isolated from streptavidin agarose beads.
Western blot analysis of the basolateral marker Na+/K+-ATPase
demonstrated the efficient separation of the apical and
basolateral membranes. Western blot analysis of Oatp4c1
demonstrated that the transporter was enriched in the apical
membrane fraction, but not in the basolateral membrane
(Fig. 1D). Collectively, these data verified the apical expression
of the transporter in Oatp4c1-expressing MDCKII cells.
However, there is precedent showing that a transporter can
mis-localize in MDCKII cells. Expression studies in MRP4-
transfected MDCKII cells show that MRP4 traffics to the
basolateral membrane due to low expression of an adaptor
protein, NHERF1, in these cells [11,13]. However, MRP4
polarized correctly in NHERF1 expressing LLC-PK1 cells.
While the adaptor proteins facilitating Oatp4c1 trafficking are
not known, we transfected LLC-PK1 with pcDNA6.2-Oatp4c1
and determined its polarity. As observed in MDCKII cells,
Oatp4c1 also polarized to the apical membrane in LLC-PK1
cells (Fig. S1).
Despite multiple efforts and approaches to generate a single
clone of Oatp4c1 expressing MDCKII cells, immunofluorescence
studies showed that expression was not detectable in at least 70%
of the cells (Fig. S2A). Thus, to increase expression we treated cells
with sodium butyrate, which is known to enhance protein
expression. As shown in Fig. S2B and S2C, Slco4c1 mRNA and
Oatp4c1 protein expression increased in the presence of 5 mM
sodium butyrate, respectively. However, as shown in Fig. S2A the
number of cells with Oatp4c1 expression was not significantly
increased with sodium butyrate. To ensure that sodium butyrate
induced expression did not interfere with the trafficking of
Figure 1. Validation of Oatp4c1 expression and subcellular localization in MDCKII cells. (A) Western blot analysis for Oatp4c1 expression.
Protein lysates (50 mg per lane) from MDCKII cells transfected with pcDNA (empty vector) and Oatp4c1 were prepared from cells grown in
monolayers. (B) Immunohistochemical analysis for Oatp4c1 expression. Paraformaldehyde-fixed paraffin-embedded cell sections were stained with
PA1343. Color development with NovaRed signifies Oatp4c1 staining. All sections were counterstained with hemotoxylin. Rabbit IgG was used as a
negative control. (C) Immunolocalization of Oatp4c1 in polarized MDCKII cells. Cells were double stained with Oatp4c1 (red) and ZO-1 (green). Nuclei
were stained with DAPI (blue). Center image in the Oatp4c1 panel is a single optical section of the x–y plane while top and right images represent x–z
and y–z planes, respectively, reconstructed from image stacks. The apical and basal sides can be demarcated by ZO-1 and the nuclei, respectively, in
both x–z and y–z sections. (D) Western blot analysis of Oatp4c1 in proteins isolated from either the apical (AP) or basolateral (BL) membranes of
polarized MDCKII cells. Surface proteins were isolated by biotin-streptavidin labeling on either the apical AP or BL compartment. Na+/K+-ATPase
served as a BL marker to demonstrate the relative efficiency of AP and BL membrane separation. (Magnification (406)).
doi:10.1371/journal.pone.0039641.g001
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Oatp4c1 we also performed immunofluorescence and demon-
strated that the apical polarity was maintained (Fig. S2D).
Expression and Subcellular Localization of Rat Oatp4c1 in
the Tissues
Rat Oatp4c1 has been detected in the kidney, but not liver by
northern blot analysis [5] or RT-PCR (data not shown). This
result was confirmed by western blotting (Fig. 2A). A band was
detected at ,80 kDa and reduced to ,65 kDa after deglycosyla-
tion, which is consistent with membrane protein post-translational
modification. The band at ,150 kDa did not shift after
deglycosylation, indicating that it was not a specific band. In
accord with the mRNA expression, no protein band was detected
in the rat liver. The subcellular localization of Oatp4c1 was then
assessed by immunohistochemical analysis in paraformaldehyde-
fixed paraffin-embedded liver and kidney tissue sections. To assure
the quality of the tissue specimens, the rat liver and kidney sections
were stained with anti-Abcg2, and anti-Mrp4 antibody, respec-
tively. Both tissues showed specific staining (data not shown).
Consistent with the western blot result (Fig. 2A), Oatp4c1 was not
detected in the rat liver, but Oatp4c1 stained strongly in apical
membranes of kidney tubules (Fig. 2B). No staining was observed
in tissue sections exposed to rabbit IgG, instead of primary
antibody, and membrane Oatp4c1 staining was abolished when
probing with antibody that was pre-absorbed with antigen peptide
(Fig. S3). The distinct apical expression of Oatp4c1 in rat kidney
was also demonstrated using dual staining for the basolateral
marker E-cadherin [22] and Oatp4c1 (Fig. 2C).
Given that these results were in contrast to previously reported
expression pattern in the rat kidney, we sought to develop
additional antibodies as well as the polyclonal antibody reported
previously by Mikkaichi and colleagues [5]. As shown in Fig. S3,
the apical Oatp4c1 expression was confirmed using three different
antibodies (PA1562, PA1254, and F3608), but we were not able to
observe staining, above background levels, with the antibody we
developed using the peptide reported by Mikkaichi and colleagues
[5].
Expression of Oatp4c1 in Isolated Brush-border
Membrane (BBM) and Basolateral Membrane (BLM)
Concurrently with the immunohistochemistry studies outlined
in Figs. 2 and S3, we sought to definitively demonstrate the
specificity of the PA1343 antibody used for western blot and
immunolocalization of Oatp4c1. To this end, we isolated brush
border membranes from rat kidney cortex and performed
proteomic analysis on proteins collected from apical and
basolateral microtubule membranes. BBM and BLM were isolated
from rat kidney cortex by Percoll density gradient. Western
blotting (Fig. 3A) and proteomic analysis (Fig. 3B) were applied to
analyze the proteins in the two fractions. Abcg2 (,70 KD) and
Mrp4 (,150 KD) were used as apical markers, and they were
enriched in BBM. Na+/K+-ATPase (,94 KD), a basolateral
Figure 2. Oatp4c1 expression and localization in rat kidney. (A) Western blot analysis for Oatp4c1 expression in rat tissues. Crude membrane
fractions from rat liver and kidney were prepared. PNGaseF was used for deglycosylation. Oatp4c1 was detected by PA1343. b-actin was used as a
loading control. (B) Immunohistochemical analysis for Oatp4c1 subcellular localization in rat tissues. Paraformaldehyde-fixed paraffin-embedded rat
tissue sections were stained with PA1343. Color development with NovaRed signifies Oatp4c1 staining. (C) Double immunofluorescence staining for
Oatp4c1 (green) and E-cadherin (red) in rat kidney. E-cadherin served as a basolateral marker (Magnification: 406).
doi:10.1371/journal.pone.0039641.g002
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marker, was detectable in both membrane fractions, but more so
in BLM than BBM. Oatp4c1 was only detected in BBM (Fig. 3A),
which was consistent with the immunohistochemistry results (Fig. 2
and S3).
To validate the specificity of the PA1343 antibody, the
proteome in BBM and BLM were analyzed by LC-MS/MS.
The proteins in BBM and BLM were separated by SDS-PAGE.
The gel bands of proteins eluting at 65–100 and 100–150 kDa
were excised, and underwent reduction, alkylation, and in-gel
trypsin digestion [18,19]. The abundance of the identified
proteins was determined by the total number of spectra
identified from a protein (spectral counts) [23,24], and spectral
counts .2 was used as the cutoff. Spectra from proteins with
molecular weight less than 65 kDa or more than 150 kDa were
excluded. The LC-MS/MS analysis identified 6 proteins unique
to the BBM, 19 proteins unique to the BLM, and 56 proteins
were either enriched in one membrane or equally distributed in
both membrane preparations. Among them, the spectral counts
of the SLC and ABC family with reported localization, along
are shown in Fig. 3B. The presence of the apical marker
(meprin) and basolateral marker (Na+/K+-ATPase) in each
membrane preparation are also shown. Eleven apical proteins
were predominantly in the BBM, four basolateral proteins were
enriched in the BLM, and three proteins with previously
reported apical localization were found in both fractions
(ambiguous). Four unique Oatp4c1 peptides (GVEN-
PAFVPSSPDTPRRR; RASASPSQVEVSAVASR;
TSQTHQNNSTSFQHMDENFGK; KVDITSTAXSPDFEAR)
were found only in the BBM. These qualitative data provide
Figure 3. Expression of Oatp4c1 in isolated kidney brush border membrane (BBM) and basolateral membrane (BLM) fractions. (A)
Western blot analysis for Oatp4c1 expression in BBM and BLM. Biochemical separation of membrane proteins (20 mg per lane) from rat kidney cortex
was achieved by Percoll gradient. Na+/K+-ATPase alpha 1 was used as a basolateral marker. Abcg2 and Mrp4 served as apical markers. Oatp4c1 was
detected by PA1343. (B) LC-MS/MS based proteomic analysis of ,60–150 kD proteins isolated from BBM and BLM fractions. Spectral counts detected
in protein digests obtained from ,60–150 kD sections excised from the SDS-PAGE gel. Proteins with 3 or more spectral counts in one fraction are
presented as ‘‘Apical’’ or ‘‘Basolateral’’ based on previously published data. Spectral counts indicate the number of unique peptides detected in each
fraction. (AP, apical).
doi:10.1371/journal.pone.0039641.g003
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additional, but conclusive evidence that Oatp4c1 localizes at the
apical membrane in the rat kidney cortex.
Location of Oatp4c1 in the Rat Kidney
To further gain insights on the potential physiological role of
Oatp4c1 we assessed its precise expression pattern at the organ
and nephron level. Immunohistochemical analysis showed that
Oatp4c1 is expressed densely in the renal tubules located in the
juxtamedullary cortex (Fig. 4A). To ascertain its location within
the tubule, we used double immunofluorescence to stain for
Oatp4c1 and the proximal tubule marker, aquaporin 1 [25], or a
distal tubule marker, calbindin-D28K [26]. As shown in Fig. 4B
and 4C, Oatp4c1 colocalizes with aquaporin 1, but not with
calbindin-D28K. Therefore, Oatp4c1 is expressed in the proximal
tubule within the juxtamedullary cortex, which suggests that it
localizes primarily in the proximal straight tubules (S3). Double
immunofluorescence staining was also used to access the location
of Oatp4c1 relative to major apical efflux transporters in the rat
kidney. As shown in Fig. 5, Mrp4 is expressed in the superficial
cortex (S1, S2), P-gp is expressed in the juxtamedullary cortex (S3)
and colocalizes with Oatp4c1, while Abcg2 is expressed in the
whole cortex (S1, S2, S3) and partially colocalizes with Oatp4c1.
Pharmacological Analyses of Rat Oatp4c1
To validate the functional activity of rat Oatp4c1 in MDCKII
cells and to gain further insight on the role of Oatp4c1 in the
transport of physiological substrates, we performed uptake and
inhibition studies using E3S, which was previously shown to be a
human OATP4C1 substrate [8,9]. Leuthold et al. demonstrated
that E3S uptake mediated by OATP4C1 is pH- dependent [9],
but this was in contrast to the report by Mikkaichi et al. who did
not observe a pH dependence in transport [5]. In preliminary
studies, the uptake of [3H]-E3S in MDCKII-Oapt4c1 cells was
susceptible to inhibition by 100 mM unlabeled E3S and transport
appeared to be more efficient in cells exposed to media with
pH 5.5 (Fig. S4). These data demonstrated the functionality of our
in vitro model and provided evidence that E3S is also a substrate of
rat Oatp4c1.
The transport kinetics of [3H]-E3S in MDCKII-Oatp4c1 were
studied further to determine the pH dependent differences in
transport. From a physiological perspective, relating to the
expression of Oatp4c1 in the kidney, this could be important as
the pH in urine ranges in the acidic range, under normal
conditions, but can be basic (.pH 7), under pathological
situations. Our studies showed that the time dependent uptake
of [3H]-E3S (0.5 mM) was more efficient in Oatp4c1 cells as
compared to vector transfected cells at pH 5.5 (Fig. 6A). Similar
differences were obtained for pH 4.5 and pH 7.4 (data not shown).
Comparatively, the net Oatp4c1 mediated uptake, obtained by
subtracting the transport in vector transfected cells, was more
efficient at pH 4.5 and pH 5.5 than at pH 7.4 (Fig. 6B).
To obtain quantitative estimates of the pH dependent
differences in transport, we then examined the concentration
dependent uptake (1 min) of [3H]-E3S and estimated transport
kinetic parameters. Based on the time dependent uptake studies
(Fig. 6B), the 1 min time point was chosen to ensure that the
transport parameters were estimated during the linear phase of
uptake transport. To evaluate [3H]-E3S transport kinetics, the
initial rate of [3H] E3S uptake were determined for concentrations
ranging from 1 to 150 mM. The [3H]-E3S uptake in MDCKII-
Oatp4c1 and MDCKII-pcDNA cells at pH 5.5 is shown in
Fig. 6C, and the net uptake at pH 4.5, 5.5 and 7.4 is shown in
Fig. 6D. A sigmoid-Emax model with a Hill coefficient parameter
was fitted to the net Oatp4c1 transport data. Parameters (Table 1)
were estimated by nonlinear regression. The Michaelis-Menten
Km-equivalent parameter, S50, at pH 7.4 (21.563.6 mM) was
comparable to the reported Km (26.664.9 mM) for human
OATP4C1 at pH 7.4 [8]. In our study, there was a trend toward
increasing S50 with a decrease in pH while the estimated Tmax was
5- and 4-fold higher at pH 4.5 and pH 5.5, respectively, than the
Tmax estimate at pH 7.4. In addition, the estimated Hill coefficient
value of 2.6 at pH 7.4 suggests positive transport cooperativity.
Using the estimated transport parameters we then determined
the uptake transport clearance as a function of [3H]-E3S
concentration. As shown in Fig. 7 the uptake transport clearance
n=Sð Þ is constant at concentrations below the S50 value, but
decreases rapidly as the substrate concentration saturates the
transporter. This analysis also demonstrates that the transporter
uptake clearance is 10–20 fold higher at acidic pH conditions.
Having validated E3S as an Oatp4c1 substrate, we next
attempted to determine the interaction of Oatp4c1 with potential
physiological substrates by studying their capacity to inhibit
transport of this prototypical substrate. Mikkaichi and colleagues
had previously reported that OATP4C1 transports T3 and T4 as
well as ouabain and digoxin [5]. In addition, in-vivo studies by
Toyohara and colleagues suggested that OATP4C1/Oatp4c1 is
involved in the elimination of uremic toxins [10]. However, their
report included only in vivo data without in vitro confirmation
[10]. In this study we sought to confirm the interaction of these
purported OATP4C1/Oatp4c1 substrates. [3H]-E3S (0.5 mM)
uptake was determined in the absence and presence of 100 mM
various compounds for 1 min at pH 5.5 (Fig. 8A) or 7.4 (Fig. 8B).
[3H]-E3S uptake was significantly inhibited by T4 at pH 5.5, and
significantly stimulated by the presence of T3 at both pH 5.5 and
7.4. In addition, [3H]-E3S accumulation was significantly higher
with T3 addition than control (without T3) in both Oatp4c1-
expressing and vector-transfected cells (Fig.S5). Digoxin and
ouabain did not change Oatp4c1-mediated uptake. Interestingly,
uremic toxins (kynurenic acid, indoxyl sulfate, hippuric acid and
trans-aconitic acid), uric acid, citric acid, and riboflavin did not
change Oatp4c1-mediated E3S uptake at both pH 5.5 and
pH 7.4. Additional studies with either digoxin as a model substrate
or by direct measurement of uremic toxin uptake in MDCKII-
Oatp4c1 cells are needed to definitively determine if uremic toxins
are Oatp4c1 substrates and/or inhibitors.
The driving force for Oatp4c1/OATP4C1 mediated transport
is currently not known. Examination of the Oatp4c1 and
OATP4C1 primary amino acid sequences by Mikkaichi and
colleagues revealed that a potential ATP binding site (Walker A
motif) was present [5]. However, an ATP-depletion assay revealed
that OATP4C1 mediated transport of T3 was not ATP-dependent
at pH 7.4 [5]. To examine whether rat Oatp4c1-mediated [3H]-
E3S transport is ATP-dependent, the effect of ATP depletion on
its accumulation was assessed. Cells were incubated with either
uptake buffer or buffer lacking glucose, but supplemented with
20 mM 2-deoxy-D-glucose and 10 mM NaN3 at pH 5.5 and
Figure 4. Oatp4c1 localization in paraformaldehyde-fixed paraffin-embedded rat kidney tissue sections. Paraformaldehyde-fixed
paraffin-embedded kidney sections were stained with antibodies as indicated. Following staining with PA1343 antibody, color development with
NovaRed signifies Oatp4c1 staining (A). Sections were double-stained with PA1343 (B, C, red) and the proximal tubule marker AQP1 (B, green) or the
distal tubule marker calbindin (C, green). Nuclei (blue) were stained with DAPI (Magnification: 46 (A), 106 (B, C)).
doi:10.1371/journal.pone.0039641.g004
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pH 7.4. The results showed that Oatp4c1-mediated [3H]-E3S
uptake did not change under ATP-depleted condition (Fig. S6). In
addition, [3H]-E3S intracellular concentrations in Oatp4c1-
expressing and vector-transfected MDCKII cells were higher
under ATP-depleted condition at pH 5.5 (Fig. S6A), suggesting
the presence of an endogenous ATP-dependent efflux transporter,
possibly Mrp1, in the MDCKII cells [27,28].
Discussion
In the present study, we undertook a comprehensive approach
to determine the subcellular localization of Oatp4c1 in polarized
epithelium. Our studies definitively demonstrated that Oatp4c1 is
expressed at the apical membrane in the rat proximal tubule. Our
approach included a variety of complementary methods to verify
this observation. Western blotting demonstrated that the antibody
used recognizes a protein of the appropriate molecular weight.
Immunohistochemical and immunofluorescence analysis revealed
that the protein traffics to the apical membrane of polarized
epithelium in vivo and in vitro. The immunohistochemistry results
were verified with four different antibodies, which were raised
against unique C- and N-terminal peptides. In addition,
biochemical separation of apical and basolateral membranes from
polarized cells in vitro and proximal rat kidney tubules confirmed
the location of Oatp4c1 at the brush border membranes by
western blot and proteomic analyses. Furthermore, the proteomic
analyses provide additional validation for the Oatp4c1 antibody
specificity.
Figure 5. Oatp4c1 colocalization with major efflux transporters in the kidney cortex. Paraformaldehyde-fixed paraffin-embedded rat
kidney sections were stained for Oatp4c1 (red), Mrp4 (red), P-gp (green), and Abcg2 (red) (A). Sections were double stained for Mrp4 (red) and
Oatp4c1 (green); (C) P-gp (green) and Oatp4c1 (red); and (D) Abcg2 (red) and Oatp4c1 (green) (B). Yellow/orange color in merged panels indicates
colocalization. Nuclei (blue) were stained with DAPI. Images presented in panel 5A were stitched from six individual images using NIH Image J with
Fiji plugin (Magnification: 46 (A), 106 (B–D)).
doi:10.1371/journal.pone.0039641.g005
Figure 6. Characteristics of Oatp4c1-mediated E3S transport. Time dependent [3H]-E3S uptake at pH 5.5 by MDCKII-pcDNA and MDCKII-
Oatp4c1 cells during incubation with 0.5 mM [3H]-E3S (A). Time dependent Oatp4c1 mediated uptake of [3H]-E3S at pH 4.5, 5.5 and 7.4 (B).
Concentration dependent [3H]-E3S uptake in MDCKII-pcDNA and MDCKII-Oatp4c1 cells after incubation at pH 5.5 for 1 min (C). Concentration
dependent Oatp4c1 mediated uptake (1 min) of [3H]-E3S at pH 4.5, 5.5 and 7.4 (D). GF: GF120918, MTX: methotrexate. Each point represents the
mean 6 S.D. of triplicates. *p,0.05, significant differences from control.
doi:10.1371/journal.pone.0039641.g006
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This extensive validation of the in vitro trafficking and in vivo
subcellular localization was deemed necessary as our results were
not in accordance with previous reports. Initially, Oatp4c1 was
shown to localize at the basolateral membrane in the rat proximal
tubule [5], and a subsequent report showed similar expression
pattern of human OATP4C1 in transgenic rats harboring human
SLCO4C1 [10]. These authors hypothesized that basolateral
expression of Oatp4c1 worked in tandem with an apical efflux
transporter to efficiently transport substrates across the kidney
epithelium and into the urine [5,10]. The contradictory finding in
the original report by Mikkaichi and colleagues may have been a
result of limited validation performed with the previous antibody
in that study [5]. Our attempt to develop this polyclonal antibody
[5], using the reported 11 amino acid peptide antigen, did not
yield a reagent that was amenable to immunohistochemistry (Fig.
S3). The results of the transgenic OATP4C1 expression pattern
reported by Toyohara et al. [10], however, are more difficult to
reconcile. In their publication, they present evidence that
OATP4C1 localizes in the basolateral membrane of renal tubule
epithelium in transgenic rats. Provided that the anti-OATP4C1
antibody recognized the correct transgenic protein, one potential
explanation for the observed differences in the subcellular
localization could be aberrant trafficking of the human OATP4C1
protein in the transgenic rats.
It is not without precedent that antibodies used to detect
transporter proteins result in controversial findings [29,30]. To
avoid potential misinterpretation of results due to antibody
immunoreactivity, we also applied two-dimensional LC/MS-MS
analysis to identify the proteome in brush border and basolateral
membranes isolated from the rat kidney cortex. The results of this
study validated our western blot and immunostaining results with
the polyclonal antibody PA1343. Some of the most abundant
proteins, such as Na+/K+-ATPase or, rBat, SGLT2, TSC or
NKCC2, were detectable in both membrane fractions, showing
lack of absolute efficiency in the separation of the two membrane
fractions. Cross-contamination between the two fractions was also
observed in previous reports using the same method [31,32].
However, these proteins were sufficiently enriched in the
appropriate fraction suggesting adequate separation of basolateral
and apical membranes. In all, the LC-MS/MS analyses identified
eighteen membrane transporter proteins (Fig. 3B). Based on
previous knowledge, fifteen of these proteins, including Oatp4c1,
were enriched or uniquely identified in the appropriate fraction
(apical or basolateral) and three proteins (ambiguous) were equally
present in both preparations (Fig. 3B). Four unique Oatp4c1
sequence peptides were found only in BBM but not in BLM.
These results are in agreement with the findings from western
blotting and immunohistochemical analyses and definitively
demonstrate that Oatp4c1 is localized at the apical membrane
in the rat proximal tubule.
Previous studies have shown the expression of several organic
anion transporters in the kidney [3,33,34,35,36,37,38]. These
transporters include: Oatp1a1 (previously Oatp1), Oatp1a3v1
(previously OAT-K1), Oatp1a3v2 (previously OAT-K2), Oatp1a5
(previously Oatp3), and Oatp2a1 (previously PGT). Oatp1a1 is
expressed at the apical membrane of the proximal tubule S3
segment in the outer medulla [3]. Oatp1a3v1 was detected in the
brush-border membranes isolated from rat kidney by western
blotting [4], and both of Oatp1a3v1 and Oatp1a3v2 showed a
functionally apical uptake in cell systems [39]. Oatp1a5 mRNA is
highly expressed in rat kidney [40], but its subcellular localization
has not been determined yet. Oatp2a1 localizes at the apical
surface of rat collecting ducts, glomerular endothelial and
mesangial cells, but not in proximal tubules [34]. Our biochemical
membrane separation and LC-MS/MS analysis of BBM and
BLM isolated from rat kidney cortex, which is rich in proximal
tubules, demonstrated that Oatp1a3 was only detected in BBM
not in BLM (Figure 3B). This was in accord with previous reports
[4]. Additionally, a single peptide of Oatp1a1 was detected in the
BBM, but that observation was below the threshold limit of 2
unique peptides and was not included in Figure 3B. The functional
reason for colocalization of Oatp1a3 with Oatp4c1 is not obvious
and additional studies are required to determine if these proteins
have common substrates and the relative affinity differences for
those substrates. In contrast, OATP4C1 is the only reported
OATP in human proximal tubules. The different expression
profile between rat and human suggests the importance of
OATP4C1 and indicates potential difficulties in interspecies
scaling and extrapolation.
In this study, we found Oatp4c1 is expressed primarily at the
apical membrane in the proximal straight tubule (S3), suggesting
its potential role in renal reabsorption of substrates. In agreement
with previous studies, we showed that E3S is an Oatp4c1
substrate. Oatp4c1-mediated E3S uptake was inhibited by T4
and enhanced by T3, suggesting that T4 is a substrate/inhibitor
and T3 is an enhancer. Both T3 and T4 have been reported as
OATP4C1 substrates [5], and Yamaguchi et al. has shown that T3
decreases OATP4C1-mediated E3S transport at pH 7.4 [8].
Although this is not consistent with our data, it may be attributed
to differences between the rat Oatp4c1 and human OATP4C1,
which share 80.4% homology. However, digoxin, ouabain, and
MTX, which are reported OATP4C1 substrates, did not change
Oatp4c1-mediated E3S uptake in our current work. This is
Table 1. Transport kinetic parameters of Oatp4c1-mediated
E3S transport at pH 4.5, 5.5 and 7.4 (mean 6 S.E.).
pH 4.5 pH 5.5 pH 7.4
Tmax [(pmol/min )/mg
protein]
612.66109.7* 484. 0650.4*** 129.3611.0**
S50 [mM] 60.5622.7 49.368.8 21.563.6
n, Hill Coefficient 1.160.2 1.560.2 2.661.0
The parameters were estimated by fitting a sigmoid-Emax model to the data.
Statistical analysis was performed by two-way ANOVA with Bonferroni post-hoc
test for all pairwise comparisons. *, **, *** p,0.05 indicate significant
differences between pH 4.5 and 5.5, pH 4.5 and 7.4, and pH 5.5 and 7.4,
respectively.
doi:10.1371/journal.pone.0039641.t001
Figure 7. The effect of pH on uptake transport clearance. The
uptake clearance n=Sð Þ was estimated using the parameter estimates in
Table 1. The solid lines show the best fit to the data using
n=S~Vmax:S
n{1

Sn50zS
n
 
obtained from [3H]-E3S uptake (Fig. 6).
doi:10.1371/journal.pone.0039641.g007
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consistent with the results of Yamaguchi et al. in MDCKII-
OATP4C1 cells who showed that E3S uptake was not inhibited by
digoxin and vice versa [8]. A similar observation was made for T3
and digoxin [5,8]. Collectively, these data provide evidence that
OATP4C1, and possibly Oatp4c1, possess multiple substrate
recognition sites. One recognizes E3S/T3, and another that
recognizes digoxin. The identification of Oatp4c1 substrates
should be investigated further so that its physiological role as well
as its function in the renal disposition of drugs and/or their
metabolites can be understood.
With respect to physiological substrates, Toyohara and
colleagues showed that OATP4C1 transgenic rats had decreased
uremic toxin plasma concentrations in the 5/6 nephrectomy renal
failure model as compared to the same model established wild-type
rats [10]. The authors suggested that this is consistent with the
model of basolateral uptake by OATP4C1 and apical efflux by
another transporter. However, in this study, we demonstrated that
Oatp4c1 is expressed in the apical membranes and functions as an
uptake transporter, thereby suggesting a function in renal
reabsorption, not tubular secretion. Therefore, there may be
other basolateral uptake or apical efflux transporters involved in
renal elimination of uremic toxins. For example, Oat1 and Oat3,
which are expressed at basolateral membrane in proximal tubule
[41], have been shown to be responsible for indoxyl sulfate and
hippuric acid uptake from blood into tubular cells [42]. Moreover,
the down-regulation of Oat1 and Oat3 expression in chronic renal
failure model may result in the uremic toxin accumulation [43]. As
for the role of apical efflux transporters, hippuric acid, indoxyl
sulfate and kynurenic acid have been shown to inhibit MRP4-
mediated MTX uptake and ABCG2-mediated E3S uptake in
inverted membrane vesicles [44]. Furthermore, ABCG2-mediated
transport is less efficient at higher pH (i.e., .pH 7.0) [45,46],
which may prevail under pathophysiological conditions in the
proximal tubules. Thus, impaired efflux by an ABC transporter
may also provide an explanation for increased uremic toxin
accumulation in the blood of animals in the renal failure models
[10]. Clearly, more studies are required to elucidate the role of
different transporters in human kidney pathophysiology and in the
animal models of renal failure.
The pH dependence of OATP mediated transport has been
demonstrated in several rodent and human OATP proteins
[9,47,48,49]. However, the driving force responsible for Oatp4c1
mediated transport is not fully understood. Mikkaichi et al. showed
that pH did not affect OATP4C1-mediated uptake [5], while
Leuthold et al. showed that E3S and T3 uptake are significantly
higher at extracellular pH 6.5 than pH 8.0 in Xenopus laevis oocytes
expressing OATP4C1 [9]. In this study, we demonstrated that
Oatp4c1-mediated E3S uptake was pH dependent. In our
estimates, Tmax was 4-fold higher at pH 5.5 than at pH 7.4 and
uptake clearance was 10–20 fold higher at acidic pH. The
observed pH-dependent Oatp4c1-mediated uptake may be a
consequence of altered ionization state of the substrate molecule.
However, with a pKa of 2 [45], the ionization state of E3S is
essentially constant under our experimental conditions (pH 4.5–
7.4). Therefore, any changes in E3S uptake from pH 4.5 to 7.4
should be a result of the pH gradient and may involve HCO3
2
exchange. Further studies examining substrate uptake in HCO3
2
replete and depleted conditions are needed to confirm the
potential role of an organic anion/HCO3
2 exchange mechanism.
In addition, the pH in renal proximal tubules of rats is acidic
[50,51,52,53] and pH dependent changes in protein structure may
also be important for substrate transport [45].
In conclusion, our data collectively demonstrate that rat
Oatp4c1 polarizes to the apical membranes in in vitro cell models
(transfected MDCKII, LLC-PK1 cells), as well as in the rat kidney
proximal tubules, which suggests that Oatp4c1 is involved in renal
reabsorption. [9]The Oatp4c1-mediated E3S uptake is ATP-
independent and pH-dependent, suggesting that pH gradient
could be the driving force for Oatp4c1 mediated transport. In
addition, our transport data corroborate previous data that
Figure 8. The effect of uremic toxins and anionic physiological substances on Oatp4c1-mediated E3S transport. Inhibition of Oatp4c1-
mediated [3H]-E3S uptake (1 min) was determined in the absence (control) and presence of various compounds (100 mM) at pH 5.5 (A) and 7.4 (B).
Oatp4c1-mediated uptake was estimated after subtracting the nonspecific uptake measured in pcDNA cells treated under identical conditions. In all
studies the [3H]-E3S concentration was 0.5 mM. GF: GF120918, MTX: methotrexate. Each point represents the mean 6 S.D. of triplicates. *p,0.05,
significant differences from control.
doi:10.1371/journal.pone.0039641.g008
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Oatp4c1 possesses multiple binding sites, but these results require
further verification.
Supporting Information
Figure S1 Immunolocalization of Oatp4c1 in polarized
LLC-PK1 cells. Cells were double stained with Oatp4c1 (red)
and ZO-1 (green). Nuclei were stained with DAPI (blue). Center
image in the Oatp4c1 panel is a single optical section of the x–y
plane while top and right images represent x–z and y–z planes,
respectively, reconstructed from image stacks. The apical and
basal sides can be demarcated by ZO-1 and the nuclei,
respectively, in both x–z and y–z sections.
(TIFF)
Figure S2 Effect of sodium butyrate (NaB) on Oatp4c1
expression and subcellular localization in MDCKII cells.
MDCKII-pcDNA and MDCKII-Oatp4c1 cells were treated with
1 or 5 mM NaB for 24 hr. Oatp4c1 expression (red) was assessed
in cells grown in monolayers (A) and cell pellets were collected,
lysed and subjected to PCR for Slco4c1 mRNA expression (B) or
western blot for Oatp4c1 protein expression (C). 18 s and b-actin
were used as loading controls in panels B and C, respectively.
Oatp4c1 subcellular localization was assessed in polarized
MDCKII cells by confocal microscopy (D). After treatment with
5 mM NaB for 24 hr, cells were double stained with Oatp4c1
(red) and ZO-1 (green). Nuclei were stained with DAPI (blue).
Center image in the Oatp4c1 panel is a single optical section of the
x–y plane while top and right images represent x–z and y–z planes,
respectively, reconstructed from image stacks. The apical and
basal sides can be demarcated by ZO-1 and the nuclei,
respectively, in both x–z and y–z sections.
(TIFF)
Figure S3 Apical Oatp4c1 localization in rat kidney
tubules was verified by four different antibodies.
Paraformaldehyde-fixed paraffin-embedded rat kidney tissue
sections were stained with different rabbit polyclonal anti-Oatp4c1
antibodies, as indicated. Color development with NovaRed
signifies Oatp4c1 staining. All sections were counterstained with
hematoxylin. Rabbit IgG was used as a negative control. Antibody
specificity (PA1343) was also demonstrated by pre-absorbing the
antibody with antigen peptide (STITVEEDLNKIENEG) over-
night at 4uC prior to use. PA1556 was generated against the
peptide (SPDFEARAGKC) previously reported by Mikkaichi and
colleagues [5].
(TIFF)
Figure S4 Oatp4c1 mediated uptake of [3H]-E3S is
inhibited by E3S. MDCKII-pcDNA and MDCKII-Oatp4c1
cells were incubated with 0.5 mM [3 H]-E3S in the absence
(control) and presence of 100 mM unlabeled E3S for 1 min at
pH 5.5 (black bars) and 7.4 (white bars). Oatp4c1 mediated uptake
was calculated after subtraction of nonspecific uptake by pcDNA
cells. Each column represents the mean 6 S.D. of triplicates.
Statistical analysis was performed with unpaired student’s t-test.
*p,0.05, significant differences from control.
(TIFF)
Figure S5 Inhibition of [3H]-E3S uptake by various
compounds. MDCKII-pcDNA and MDCKII-Oatp4c1 cells
were incubated with 0.5 mM [3H]-E3S in the absence (control)
and presence of various compounds (100 mM) for 1 min at pH 5.5
(A) and 7.4 (B). Each point represents the mean 6 S.D. of
triplicates.
(TIFF)
Figure S6 Effect of ATP on [3H]-E3S uptake via
Oatp4c1. (A) MDCKII-pcDNA (white bars) and MDCKII-
Oatp4c1 cells (black bars) were incubated with 0.5 mM [3H]-E3S
for 1 min at pH 5.5 and pH 7.4. Twenty minutes prior to the
transport experiment, and for the duration of transport, cell
medium was replaced with medium that contained 20 mM 2-
deoxy-D-glucose and 10 mM NaN3 without D-glucose. (B)
Oatp4c1-mediated uptake was calculated after subtraction of
nonspecific uptake by pcDNA cells. Each column represents the
mean 6 S.D. of triplicates.
(TIFF)
Acknowledgments
We thank Drs. John Schuetz, Philip Empey, and Mary Vore for helpful
comments and suggestions. We also thank Dr. Mamta Goswami for
technical assistance with cloning and transfection and Dr. Lipeng Wang for
technical assistance with histology procedures.
Author Contributions
Performed the experiments: KK HZ. Analyzed the data: KK HZ PJM
ML. Contributed reagents/materials/analysis tools: HZ. Wrote the paper:
KK HZ PJM ML.
References
1. Nies AT, Schwab M, Keppler D (2008) Interplay of conjugating enzymes with
OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of
drugs. Expert Opin Drug Metab Toxicol 4: 545–568.
2. Ito K, Suzuki H, Horie T, Sugiyama Y (2005) Apical/basolateral surface
expression of drug transporters and its role in vectorial drug transport. Pharm
Res 22: 1559–1577.
3. Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, et al. (1996)
Immunologic distribution of an organic anion transport protein in rat liver
and kidney. American Journal of Physiology - Gastrointestinal and Liver
Physiology 271: G231–G238.
4. Masuda S, Saito H, Nonoguchi H, Tomita K, Inui K-i (1997) mRNA
distribution and membrane localization of the OAT-K1 organic anion
transporter in rat renal tubules. FEBS Letters 407: 127–131.
5. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, et al. (2004)
Isolation and characterization of a digoxin transporter and its rat homologue
expressed in the kidney. Proc Natl Acad Sci U S A 101: 3569–3574.
6. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, et al. (2006) Expression
profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A
resource for investigations into drug disposition. Xenobiotica 36: 963–988.
7. Chu X-Y, Bleasby K, Yabut J, Cai X, Chan GH, et al. (2007) Transport of the
Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion
Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug
Resistance P-glycoprotein. Journal of Pharmacology and Experimental Thera-
peutics 321: 673–683.
8. Yamaguchi H, Sugie M, Okada M, Mikkaichi T, Toyohara T, et al. (2010)
Transport of estrone 3-sulfate mediated by organic anion transporter
OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin
in OATP4C1. Drug Metab Pharmacokinet 25: 314–317.
9. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, et al. (2009)
Mechanisms of pH-gradient driven transport mediated by organic anion
polypeptide transporters. Am J Physiol Cell Physiol 296: C570–582.
10. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, et al. (2009)
SLCO4C1 Transporter Eliminates Uremic Toxins and Attenuates Hypertension
and Renal Inflammation. Journal of the American Society of Nephrology 20:
2546–2555.
11. Lai L, Tan TMC (2002) Role of glutathione in the multidrug resistance protein 4
(MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues.
Biochem J 361: 497–503.
12. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, et al. (2004) Mrp4
confers resistance to topotecan and protects the brain from chemotherapy. Mol
Cell Biol 24: 7612–7621.
13. Hoque MT, Conseil G, Cole SPC (2009) Involvement of NHERF1 in apical
membrane localization of MRP4 in polarized kidney cells. Biochemical and
Biophysical Research Communications 379: 60–64.
Oatp4c1 Expression in Rat Kidney
PLoS ONE | www.plosone.org 14 June 2012 | Volume 7 | Issue 6 | e39641
14. Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, et al. (2003)
Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot
override ABCG2-mediated drug resistance. Mol Pharmacol 64: 279–288.
15. Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, et al. (1996)
Basolateral localization and export activity of the human multidrug resistance-
associated protein in polarized pig kidney cells. J Clin Invest 97: 1211–1218.
16. Goldinger JM, Khalsa BD, Hong SK (1984) Photoaffinity labeling of organic
anion transport system in proximal tubule. American Journal of Physiology -
Cell Physiology 247: C217–C227.
17. Walmsley SJ, Broeckling C, Hess A, Prenni J, Curthoys NP (2010) Proteomic
analysis of brush-border membrane vesicles isolated from purified proximal
convoluted tubules. American Journal of Physiology - Renal Physiology 298:
F1323–F1331.
18. Fukada K, Zhang F, Vien A, Cashman NR, Zhu H (2004) Mitochondrial
Proteomic Analysis of a Cell Line Model of Familial Amyotrophic Lateral
Sclerosis. Molecular & Cellular Proteomics 3: 1211–1223.
19. Zhai J, Ström A-L, Kilty R, Venkatakrishnan P, White J, et al. (2009) Proteomic
characterization of lipid raft proteins in amyotrophic lateral sclerosis mouse
spinal cord. FEBS Journal 276: 3308–3323.
20. Hirano M, Maeda K, Shitara Y, Sugiyama Y (2004) Contribution of OATP2
(OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in
Humans. Journal of Pharmacology and Experimental Therapeutics 311: 139–
146.
21. Saito H, Masuda S, Inui K-i (1996) Cloning and Functional Characterization of
a Novel Rat Organic Anion Transporter Mediating Basolateral Uptake of
Methotrexate in the Kidney. Journal of Biological Chemistry 271: 20719–20725.
22. Piepenhagen PA, Peters LL, Lux SE, Nelson WJ (1995) Differential expression of
Na(+)-K(+)-ATPase, ankyrin, fodrin, and E-cadherin along the kidney nephron.
American Journal of Physiology - Cell Physiology 269: C1417–C1432.
23. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, et al.
(2005) Comparison of Label-free Methods for Quantifying Human Proteins by
Shotgun Proteomics. Molecular & Cellular Proteomics 4: 1487–1502.
24. Liu H, Sadygov RG, Yates JR (2004) A Model for Random Sampling and
Estimation of Relative Protein Abundance in Shotgun Proteomics. Analytical
Chemistry 76: 4193–4201.
25. Sabolic I, Valenti G, Verbavatz JM, Van Hoek AN, Verkman AS, et al. (1992)
Localization of the CHIP28 water channel in rat kidney. American Journal of
Physiology - Cell Physiology 263: C1225–C1233.
26. Bindels RJ, Hartog A, Timmermans JA, van Os CH (1991) Immunocytochem-
ical localization of calbindin-D28k, calbindin-D9k and parvalbumin in rat
kidney. Contrib Nephrol 91: 7–13.
27. Goh L-B, Spears KJ, Yao D, Ayrton A, Morgan P, et al. (2002) Endogenous
drug transporters in in vitro and in vivo models for the prediction of drug
disposition in man. Biochemical Pharmacology 64: 1569–1578.
28. Qian Y-M, Song W-C, Cui H, Cole SPC, Deeley RG (2001) Glutathione
Stimulates Sulfated Estrogen Transport by Multidrug Resistance Protein 1.
Journal of Biological Chemistry 276: 6404–6411.
29. Huls M, Brown CDA, Windass AS, Sayer R, van den Heuvel JJMW, et al.
(2007) The breast cancer resistance protein transporter ABCG2 is expressed in
the human kidney proximal tubule apical membrane. Kidney Int 73: 220–225.
30. Liu B, Sun D, Xia W, Hung MC, Yu D (1997) Cross-reactivity of C219 anti-
p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on
evaluating p170(mdr-1). J Natl Cancer Inst 89: 1524–1529.
31. Murer H, Gmaj P (1986) Transport studies in plasma membrane vesicles isolated
from renal cortex. Kidney Int 30: 171–186.
32. Scalera V, Huang YK, Hildmann B, Murer H (1981) A simple isolation method
for basal-lateral plasma membranes from rat kidney cortex. Membr Biochem 4:
49–61.
33. Yang C-H, Glover KP, Han X (2009) Organic anion transporting polypeptide
(Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal
reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarbox-
ylates in rats. Toxicology Letters 190: 163–171.
34. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, et al. (2002) Prostaglandin transporter
PGT is expressed in cell types that synthesize and release prostanoids. American
Journal of Physiology - Renal Physiology 282: F1103–F1110.
35. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, et al. (2004)
Human Organic Anion Transporter 4 Is a Renal Apical Organic Anion/
Dicarboxylate Exchanger in the Proximal Tubules. Journal of Pharmacological
Sciences 94: 297–304.
36. Rizwan A, Burckhardt G (2007) Organic Anion Transporters of the SLC22
Family: Biopharmaceutical, Physiological, and Pathological Roles. Pharmaceu-
tical Research 24: 450–470.
37. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. (2002)
Molecular identification of a renal urate-anion exchanger that regulates blood
urate levels. Nature 417: 447–452.
38. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, et al. (2005)
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2
(OATP1A2). Journal of Biological Chemistry 280: 9610–9617.
39. Masuda S, Ibaramoto K, Takeuchi A, Saito H, Hashimoto Y, et al. (1999)
Cloning and Functional Characterization of a New Multispecific Organic Anion
Transporter, OAT-K2, in Rat Kidney. Molecular Pharmacology 55: 743–752.
40. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, et al. (1998) Molecular
Characterization and Tissue Distribution of a New Organic Anion Transporter
Subtype (oatp3) That Transports Thyroid Hormones and Taurocholate and
Comparison with oatp2. Journal of Biological Chemistry 273: 22395–22401.
41. Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y, et al. (2002)
Immunolocalization of Multispecific Organic Anion Transporters, OAT1,
OAT2, and OAT3, in Rat Kidney. Journal of the American Society of
Nephrology 13: 848–857.
42. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, et al. (2004)
Characterization of uremic toxin transport by organic anion transporters in the
kidney. Kidney Int 65: 162–174.
43. Deguchi T, Takemoto M, Uehara N, Lindup WE, Suenaga A, et al. (2005)
Renal Clearance of Endogenous Hippurate Correlates with Expression Levels of
Renal Organic Anion Transporters in Uremic Rats. Journal of Pharmacology
and Experimental Therapeutics 314: 932–938.
44. Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, et al.
(2011) Uremic toxins inhibit transport by breast cancer resistance protein and
multidrug resistance protein 4 at clinically relevant concentrations. PLoS One 6:
e18438.
45. Li L, Sham YY, Bikadi Z, Elmquist WF (2011) pH-Dependent Transport of
Pemetrexed by Breast Cancer Resistance Protein. Drug Metabolism and
Disposition 39: 1478–1485.
46. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MAJ, et al.
(2007) The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-
Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate
Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro
Drug Transport Models. Molecular Pharmacology 71: 240–249.
47. Satlin LM, Amin V, Wolkoff AW (1997) Organic Anion Transporting Polypeptide
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